Abbosynagis

Abbosynagis Uses, Dosage, Side Effects, Food Interaction and all others data.

Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. Abbosynagis is expressed from a stable murine (mouse) myeloma cell line (NS0). Abbosynagis is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF)

Synagis exhibits neutralizing and fusion-inhibitory activity against Respiratory syncytial virus (RSV). These activities inhibit RSV replication or spread. Synagis is given to prevent the development of lower respiratory tract disease in pediatric patients.

Table Of contents

• Abbosynagis
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Abbosynagis
Availability	Prescription only
Generic	Palivizumab
Palivizumab Other Names	Palivizumab
Related Drugs	ribavirin, Synagis, respiratory syncytial virus immune globulin, RespiGam
Type
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	Israel
Last Updated:	September 19, 2023 at 7:00 am

Uses

Abbosynagis is a monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients.

For prophylaxis of respiratory diseases casued by respiratory syncytial virus.

Abbosynagis is also used to associated treatment for these conditions: Infections, Respiratory Syncytial Virus

How Abbosynagis works

Abbosynagis binds to the fusion glycoprotein of RSV. This prevents its binding and uptake by host cellular receptors.

Food Interaction

No interactions found.

Abbosynagis Disease Interaction

Major: platelet disorders

Half Life

18-20 days (in adults)

Innovators Monograph

You find simplified version here Abbosynagis